Novadip Biosciences

Executive Summary

Novadip Biosciences is a Belgian biotechnology company developing regenerative tissue products for bone repair, targeting large bone defects, non-unions, and spinal fusion. Founded in 2013, the company aims to provide a single-treatment approach that accelerates healing, addressing significant unmet medical needs. While financial details are undisclosed, Novadip's pipeline likely includes lead candidates such as NVD-003 (autologous bone graft) and NVD-005 (allogeneic product) in clinical development. The company has raised funding from investors like SRIW and Sambrinvest, and its technology platform uses 3D scaffolds of autologous or allogeneic stem cells. Key upcoming catalysts include Phase 2b data for NVD-003 in long bone non-unions, potential FDA interaction for a pivotal trial design, and a possible Series C financing round to support late-stage development. If successful, Novadip could become a leader in bone regeneration, but clinical and regulatory risks remain.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b topline data for NVD-003 in long bone non-unions70% success
• Q4 2026FDA end-of-Phase 2 meeting to discuss pivotal trial design80% success
• Q1 2027Series C financing to fund Phase 3 preparation60% success